Sana Biotechnology Inc vs Stitch Fix Inc — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Stitch Fix Inc trades at $2.9 (market cap $396.27M). The key difference: Sana Biotechnology Inc is far larger — about 2.6× Stitch Fix Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SFIX | |
|---|---|---|
Market Cap | $1.03B | $396.27M |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $5.80 |
52-Week Low | $2.68 | $2.89 |
Enterprise Value | $946.04M | $283.99M |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, as the stock faces technical bearish pressure despite showing fundamental improvements. The company has demonstrated progress in its turnaround with three consecutive quarterly earnings beats and narrowing losses, though it remains unprofitable with a -1.43% net margin. Recent news highlights ongoing legal challenges and AI-driven growth initiatives, while analyst sentiment remains cautious with 64% hold ratings.
The outlook suggests a company in transition - improving operational metrics and debt-free balance sheet provide stability, but sustained profitability remains the key challenge. Near-term catalysts include Q2 2026 earnings results and continued execution of AI personalization strategy, though competitive pressures and consumer spending volatility present ongoing risks.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →